Latest 13 stories · newest Oct 21, 2026
Abbott plans to separate its Nutrition business into an independent publicly traded company by the end of 2027. This move aims to unlock distinct growth strategies for both Abbott and its new Nutrition subsidiary, which will retain brands like Similac and Ensure.
Abbott reported strong Q3 2026 sales and adjusted EPS growth, reaffirming full-year guidance. They announced several key regulatory approvals. Company executives expressed optimism about sustainable growth.
Freenome's SimpleScreen CRC, a blood-based colorectal cancer screening test, received FDA approval and will be commercialized in the U.S. by Abbott to help millions of Americans who are overdue for screening.
Abbott reported 13% sales growth and significantly raised its adjusted EPS guidance. The company reaffirmed its sales outlook as it returned $2.1 billion to shareholders.
The same ABT feed as JSON for your bot or app:
GET https://api.brieftape.com/v1/tickers/ABT/newsSTART FREE